Bank of Nova Scotia’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.87M | Sell |
13,561
-4,067
| -23% | -$798K | ﹤0.01% | 722 |
|
|
2026
Q1 | $3.45M | Sell |
17,628
-48,834
| -73% | -$9.49M | 0.01% | 655 |
|
|
2025
Q4 | $11.5M | Buy |
66,462
+50,471
| +316% | +$9.19M | 0.02% | 453 |
|
|
2025
Q3 | $3.05M | Buy |
15,991
+1,652
| +12% | +$293K | 0.01% | 635 |
|
|
2025
Q2 | $2.58M | Buy |
14,339
+962
| +7% | +$167K | 0.01% | 635 |
|
|
2025
Q1 | $2.26M | Sell |
13,377
-3,774
| -22% | -$620K | 0.01% | 595 |
|
|
2024
Q4 | $2.59M | Buy |
17,151
+427
| +3% | +$66.4K | ﹤0.01% | 640 |
|
|
2024
Q3 | $2.6M | Buy |
16,724
+2,795
| +20% | +$417K | 0.01% | 602 |
|
|
2024
Q2 | $1.91M | Sell |
13,929
-3,531
| -20% | -$484K | ﹤0.01% | 650 |
|
|
2024
Q1 | $2.32M | Buy |
17,460
+2,845
| +19% | +$369K | ﹤0.01% | 632 |
|
|
2023
Q4 | $2.02M | Buy |
14,615
+3,521
| +32% | +$463K | ﹤0.01% | 653 |
|
|
2023
Q3 | $1.35M | Buy |
11,094
+1,358
| +14% | +$181K | ﹤0.01% | 660 |
|
|
2023
Q2 | $1.37M | Buy |
9,736
+1,373
| +16% | +$189K | ﹤0.01% | 616 |
|
|
2023
Q1 | $1.18M | Sell |
8,363
-1,665
| -17% | -$238K | ﹤0.01% | 673 |
|
|
2022
Q4 | $1.57M | Sell |
10,028
-15,768
| -61% | -$2.27M | ﹤0.01% | 712 |
|
|
2022
Q3 | $3.17M | Buy |
25,796
+10,390
| +67% | +$1.37M | 0.01% | 526 |
|
|
2022
Q2 | $2.05M | Sell |
15,406
-5,504
| -26% | -$750K | ﹤0.01% | 685 |
|
|
2022
Q1 | $2.86M | Sell |
20,910
-10,153
| -33% | -$1.42M | ﹤0.01% | 736 |
|
|
2021
Q4 | $5.38M | Sell |
31,063
-31,264
| -50% | -$4.76M | 0.01% | 678 |
|
|
2021
Q3 | $9.05M | Buy |
62,327
+38,166
| +158% | +$5.58M | 0.02% | 497 |
|
|
2021
Q2 | $3.19M | Sell |
24,161
-1,202
| -5% | -$157K | 0.01% | 698 |
|
|
2021
Q1 | $3.25M | Buy |
25,363
+2,194
| +9% | +$270K | 0.01% | 677 |
|
|
2020
Q4 | $2.76M | Sell |
23,169
-113,190
| -83% | -$13.8M | 0.01% | 635 |
|
|
2020
Q3 | $15.6M | Buy |
136,359
+81,903
| +150% | +$9.68M | 0.04% | 284 |
|
|
2020
Q2 | $6.21M | Buy |
54,456
+24,976
| +85% | +$2.65M | 0.02% | 387 |
|
|
2020
Q1 | $2.37M | Sell |
29,480
-444
| -1% | -$46K | 0.01% | 529 |
|
|
2019
Q4 | $3.2M | Buy |
29,924
+2,964
| +11% | +$309K | 0.01% | 599 |
|
|
2019
Q3 | $2.89M | Buy |
26,960
+4,376
| +19% | +$449K | 0.01% | 598 |
|
|
2019
Q2 | $2.3M | Sell |
22,584
-2,954
| -12% | -$284K | 0.01% | 581 |
|
|
2019
Q1 | $2.3M | Sell |
25,538
-54,332
| -68% | -$4.71M | 0.01% | 598 |
|
|
2018
Q4 | $6.65M | Buy |
79,870
+2,161
| +3% | +$203K | 0.03% | 341 |
|
|
2018
Q3 | $8.38M | Buy |
77,709
+63,000
| +428% | +$6.91M | 0.04% | 337 |
|
|
2018
Q2 | $1.62M | Sell |
14,709
-2,491
| -14% | -$259K | 0.01% | 555 |
|
|
2018
Q1 | $1.73M | Sell |
17,200
-4,121
| -19% | -$422K | 0.01% | 611 |
|
|
2017
Q4 | $2.1M | Sell |
21,321
-2,408
| -10% | -$228K | 0.01% | 603 |
|
|
2017
Q3 | $2.22M | Sell |
23,729
-7,136
| -23% | -$758K | 0.01% | 562 |
|
|
2017
Q2 | $3.43M | Sell |
30,865
-650
| -2% | -$68.7K | 0.02% | 499 |
|
|
2017
Q1 | $3.09M | Buy |
31,515
+28,455
| +930% | +$2.71M | 0.01% | 517 |
|
|
2016
Q4 | $281K | Buy |
3,060
+200
| +7% | +$17.2K | ﹤0.01% | 720 |
|
|
2016
Q3 | $242K | Buy |
2,860
+10
| +0.4% | +$840 | ﹤0.01% | 652 |
|
|
2016
Q2 | $232K | Sell |
2,850
-71,550
| -96% | -$5.45M | ﹤0.01% | 654 |
|
|
2016
Q1 | $5.32M | Buy |
+74,400
| New | +$4.99M | 0.03% | 214 |
|
|
2014
Q1 | – | Sell |
-52,074
| Closed | -$2.79M | – | 585 |
|
|
2013
Q4 | $2.79M | Buy |
52,074
+7
| +0% | +$415 | 0.01% | 261 |
|
|
2013
Q3 | $3.22M | Buy |
52,067
+1,961
| +4% | +$117K | 0.02% | 197 |
|
|
2013
Q2 | $3.04M | Buy |
+50,106
| New | +$2.98M | 0.02% | 184 |
|
Other funds holding DGX
EIG
Bank of Nova Scotia's DGX Position: Q2 2026 in Review
Bank of Nova Scotia reduced its Quest Diagnostics (DGX) stake by 23% in Q2 2026, selling an estimated $798K and leaving 13,561 shares worth $2.87M. The position accounts for ﹤0.01% of the portfolio, ranked #722.
Bank of Nova Scotia first reported a position in DGX in Q2 2013 and has held it in 45 quarters since. The position peaked at $15.6M in Q3 2020. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Bank of Nova Scotia held 13,561 shares of Quest Diagnostics worth $2.87M as of Q2 2026.
- Bank of Nova Scotia sold 4,067 Quest Diagnostics shares in Q2 2026, an estimated $798K.
- Quest Diagnostics made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q2 2026, its #722 holding.
- Bank of Nova Scotia first reported a position in Quest Diagnostics in Q2 2013 and has held it in 45 quarters since.
- Bank of Nova Scotia's Quest Diagnostics position peaked at $15.6M in Q3 2020.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.